Literature DB >> 12757400

Hydroxyethyl starch (HES) [130/0.4], a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers.

Josef Waitzinger1, Frank Bepperling, Günther Pabst, Jens Opitz.   

Abstract

OBJECTIVE: To investigate the pharmacokinetics and safety of a daily infusion of 500 mL of hydroxyethyl starch (HES) [130/0.4] 10% solution on 10 consecutive days. STUDY DESIGN AND PARTICIPANTS: An open, one-way, multiple-dose study was performed in 12 healthy male volunteers. Daily infusions over 30 minutes of 500 mL of HES (130/0.4) 10% solution were performed on 10 consecutive days. Plasma and urine HES concentrations were determined repeatedly during the study until 72 hours after the last infusion.
RESULTS: Maximum plasma HES concentrations, assessed with geometric means of 7.7 and 7.4 mg/mL, respectively, as well as the time courses of the plasma concentrations were similar on days 1 and 10 of treatment. Plasma HES concentrations 24 hours after the last infusion were 0.48 mg/mL (mean). Total plasma clearance was calculated as 23.7 and 21.8 mL/min on days 1 and 10, respectively. Urinary recoveries of 69% on day 1 and of 70% on day 10 were in good agreement.
CONCLUSION: The results clearly demonstrated that there is no relevant accumulation in plasma after repetitive infusion of the medium-molecular weight HES (130/0.4) solution, which exhibits a high renal excretion rate over 10 days. Local as well as systemic tolerability of 10 repeated doses was good.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12757400     DOI: 10.2165/00126839-200304030-00002

Source DB:  PubMed          Journal:  Drugs R D        ISSN: 1174-5886


  11 in total

1.  Pharmacokinetics and safety of 6 % hydroxyethyl starch 130/0.4 in healthy male volunteers of Japanese ethnicity after single infusion of 500 ml solution.

Authors:  Michiaki Yamakage; Frank Bepperling; Manfred Wargenau; Hideki Miyao
Journal:  J Anesth       Date:  2012-06-23       Impact factor: 2.078

Review 2.  Pharmacokinetics of hydroxyethyl starch.

Authors:  Cornelius Jungheinrich; Thomas A Neff
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  [Volume replacement in intensive care medicine].

Authors:  B Nohé; A Ploppa; V Schmidt; K Unertl
Journal:  Anaesthesist       Date:  2011-05       Impact factor: 1.041

Review 4.  Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies.

Authors:  Romuald Bellmann; Clemens Feistritzer; Christian J Wiedermann
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

Review 5.  CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients.

Authors:  Christiane Hartog; Konrad Reinhart
Journal:  Intensive Care Med       Date:  2009-06-17       Impact factor: 17.440

Review 6.  PRO: hydroxyethylstarch can be safely used in the intensive care patient--the renal debate.

Authors:  Joachim Boldt
Journal:  Intensive Care Med       Date:  2009-06-17       Impact factor: 17.440

Review 7.  Crystalloid and Colloid Compositions and Their Impact.

Authors:  Elke Rudloff; Kate Hopper
Journal:  Front Vet Sci       Date:  2021-03-31

8.  Effect of rapid plasma volume expansion during anesthesia induction on haemodynamics and oxygen balance in patients undergoing gastrointestinal surgery.

Authors:  Fu-qing Lin; Cheng Li; Li-jun Zhang; Shu-kun Fu; Guo-qiang Chen; Xiao-hu Yang; Chun-yan Zhu; Quan Li
Journal:  Int J Med Sci       Date:  2013-02-15       Impact factor: 3.738

9.  The impact of 30 ml/kg hydroxyethyl starch 130/0.4 vs hydroxyethyl starch 130/0.42 on coagulation in patients undergoing abdominal surgery.

Authors:  Chryssoula Staikou; Anteia Paraskeva; Argyro Fassoulaki
Journal:  Indian J Med Res       Date:  2012-09       Impact factor: 2.375

10.  Quality of life and pruritus in patients with severe sepsis resuscitated with hydroxyethyl starch long-term follow-up of a randomised trial.

Authors:  Piotr Wittbrodt; Nicolai Haase; Dominika Butowska; Robert Winding; Jesper B Poulsen; Anders Perner
Journal:  Crit Care       Date:  2013-02-25       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.